https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis
Zolgensma Creation Story Reveals Truths About Drug Pricing — ProPublica
Jun 16, 2025 - Taxpayers and charities helped develop Zolgensma. Then it debuted at a record price, ushering in a new class of wildly expensive drugs. Its story upends the...
creation storydrug pricingzolgensmarevealstruths
https://idec.org.br/noticia/zolgensma-o-remedio-mais-caro-do-mundo
Zolgensma, o remédio mais caro do mundo | Idec - Instituto Brasileiro de Defesa do Consumidor
Tratamento de R$ 2,8 milhões levanta debate sobre falta de transparência no setor farmacêutico
zolgensmamaiscaromundoidec
https://mdaquest.org/fda-approves-avexis-zolgensma-for-treatment-of-spinal-muscular-atrophy-in-pediatric-patients/
FDA Approves AveXis’ Zolgensma for Treatment of Spinal Muscular Atrophy in Pediatric Patients -...
Oct 9, 2024 - Quest strives to empower, inform, and engage with updates on research and clinical trials, conversations with thought leaders, and stories that explore...
spinal muscular atrophypediatric patientsfdazolgensmatreatment
https://www.bkk-dachverband.de/versorgung/arzneimittel/schlechte-noten-fuer-zolgensma
Schlechte Noten für Zolgensma - BKK Dachverband
Anfang November war es endlich so weit. Der Gemeinsame Bundesausschuss (G-BA) bewertete das Zwei-Millionen-Medikament Zolgensma vom Hersteller Novartis. Als...
schlechte notenbkk dachverbandzolgensma